Filgrastim biosimilar - CT Arzneimittel

Drug Profile

Filgrastim biosimilar - CT Arzneimittel

Alternative Names: Biograstim (CT Arzneimittel)

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator CT Arzneimittel
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 16 May 2016 Launched for Neutropenia in Slovakia and Lithuania (IV), (SC) before May 2016
  • 15 Mar 2016 Biomarkers information updated
  • 04 Apr 2011 Launched for Neutropenia in Germany, Ireland, Netherlands, Poland, Portugal and Czech Republic (IV, infusion) after September 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top